Story
Hengrui Pharma Stock Surges on $2.6 Billion GLP-1 Licensing Deal with Novo Nordisk
Summary
Shares of Jiangsu Hengrui Pharmaceuticals rallied after the company secured a licensing agreement potentially worth up to $2.6 billion with Novo Nordisk for its experimental oral obesity and diabetes drug.
Shares of Jiangsu Hengrui Pharmaceuticals Co Ltd (SS:600276) surged 4.2% on Tuesday after the company announced a significant licensing agreement with Danish pharmaceutical firm Novo Nordisk A/S (CSE:NOVOb) for an experimental weight-loss and diabetes drug.
The Agreement
The deal grants Novo Nordisk exclusive rights to develop, manufacture, and commercialize Hengrui's drug candidate, HRS-1596, in all territories outside of Greater China. HRS-1596 is a once-weekly oral GLP-1/GIP dual receptor agonist, a highly sought-after class of treatments for obesity and diabetes.
According to the announcement, the total potential value of the deal could reach up to $2.6 billion. The financial terms include:
- An upfront payment of $300 million to Hengrui.
- Additional payments contingent on achieving specific development and commercial milestones.
- Tiered royalties on future net sales in the licensed regions.
Strategic Importance and Context
AdThis agreement highlights Hengrui's successful strategy of out-licensing its innovative drug pipeline to global partners, which has been a key factor in the stock's re-rating, according to market observers. The deal provides a major validation of the company's research and development capabilities in a highly competitive therapeutic area.
The partnership also aligns with Hengrui's efforts to diversify its revenue streams beyond its traditional focus on oncology. In the first half of 2026, the company reported that its revenue from non-oncology innovative drugs grew by approximately 74% year-over-year. Hengrui has also been actively repurchasing its A-shares, including a buyback in mid-September 2026.
Market Reaction
Hengrui's stock closed at HK$46.62 in Hong Kong, outperforming the broader market, which was reportedly subdued by concerns over rising bond yields and geopolitical tensions. The positive investor reaction underscores the perceived value of the Novo Nordisk partnership and its potential to generate substantial long-term revenue for the Chinese drugmaker.
Read next
More on Stocks
Nidec Stock Tumbles Amid CEO Resignation, Planned ¥1 Trillion Impairment
Shares of Japanese motor giant Nidec Corp. extended a steep two-day selloff following reports of its CEO's planned resignation and a massive ¥1 trillion writedown linked to its struggling electric vehicle business.
Navigator Global Shares Surge on $75M Invictus Stake Sale to New York Life
The alternative asset manager's stock jumped over 8% after it announced a deal to sell a 60% stake in Invictus Capital Partners, expecting up to $75 million in total proceeds.
China Stocks Edge Higher on Policy Support Pledge; Hong Kong Slips
Mainland Chinese stocks posted modest gains after Beijing pledged further economic support, particularly for the property sector, while Hong Kong shares declined amid thin pre-holiday trading.
Hengrui Pharma Shares Rise on $2.6 Billion Obesity Drug Deal with Novo Nordisk
Jiangsu Hengrui Pharmaceuticals saw its shares climb after securing a licensing agreement with Novo Nordisk for an experimental oral obesity and diabetes drug, with the deal valued at up to $2.6 billion.